Catalyst Pharmaceuticals v. MSN Laboratories: Consent Judgment on Amifampridine Synthesis Patent
Catalyst Pharmaceuticals filed suit in the District of New Jersey against MSN Laboratories and MSN Pharmaceuticals over US8772497B2, a patent covering methods for producing 1,2-dihydropyridine-2-one compounds. The case resolved by consent judgment after 450 days, with MSN retaining the right to maintain its Paragraph IV certification.
ANDA Patent Battle Over Amifampridine Synthesis Ends by Consent
On April 5, 2023, Catalyst Pharmaceuticals, Inc. filed an infringement action in the U.S. District Court for the District of New Jersey against MSN Laboratories Private Limited and its U.S. affiliate MSN Pharmaceuticals, Inc. The suit centred on US8772497B2, which claims methods for producing 1,2-dihydropyridine-2-one compounds — the synthetic pathway underlying amifampridine, marketed by Catalyst as Firdapse for Lambert-Eaton myasthenic syndrome. The filing was triggered by MSN’s Paragraph IV certification, a statutory mechanism by which generic manufacturers challenge the validity or non-infringement of listed Orange Book patents.
The case closed on June 28, 2024, via a consent judgment — a binding court order agreed to by both parties. Critically, the consent judgment expressly preserved MSN’s right to maintain its Paragraph IV certification against the ‘497 patent, suggesting that the resolution did not constitute a full capitulation by MSN. This nuanced outcome is consistent with negotiated settlements in Hatch-Waxman litigation where market entry timing, licensing, or carve-out provisions are often the operative commercial terms, even when the underlying agreement is not fully public.
At 450 days, the timeline exceeds what might be expected for a straightforward consent resolution, suggesting substantive negotiation or parallel regulatory proceedings may have extended the process. The public record does not disclose whether royalties, an agreed market-entry date, or licensing terms accompanied the judgment. What remains significant is that MSN’s Paragraph IV certification survives, meaning future generic entry — or further patent challenge — remains legally viable under the agreed order.
Filing to Consent Judgment in 450 days
450 days — above average for a consent-judgment resolution in ANDA/Paragraph IV litigation
Consent judgment explained: what the agreed order means for both parties
Consent judgment is a court-enforceable agreed order — not a concession
A consent judgment in Hatch-Waxman litigation is a negotiated resolution entered as a binding court order. It carries the legal weight of a judicial ruling but reflects terms agreed by the parties. Unlike a judgment after trial, it does not necessarily resolve the underlying validity or infringement questions on the merits. Here, the order expressly carves out MSN’s Paragraph IV certification, signalling the settlement was structured to preserve future optionality for the generic party.
Negotiated resolutionCatalyst secures court order but MSN’s IV certification survives
Catalyst obtained a consent judgment, which provides court-backed enforceability for any agreed terms. However, the explicit preservation of MSN’s Paragraph IV certification means Catalyst did not achieve a clean victory blocking generic challenge. The ‘497 patent remains subject to potential future invalidity or non-infringement arguments. The commercial terms — whether a royalty, agreed launch date, or licensed entry — are not disclosed in the public record.
Patent survives; challenge preservedMSN retains its Paragraph IV certification — future entry remains viable
The consent judgment expressly states that MSN is not prohibited from maintaining its Paragraph IV certification under 21 U.S.C. This is a material concession by Catalyst: MSN’s legal right to continue challenging the ‘497 patent through the ANDA pathway is preserved. Depending on undisclosed commercial terms, MSN may be positioned for a negotiated or date-certain market entry into the amifampridine space, consistent with common Hatch-Waxman settlement structures.
Paragraph IV certification intactNegotiated entry pathway signals competitive pressure on amifampridine market
The survival of MSN’s Paragraph IV certification, combined with a consent judgment rather than a litigated win for Catalyst, is consistent with a structured generic-entry deal. Companies competing in the amifampridine or broader neuromuscular disorder drug space should monitor Orange Book listings for the ‘497 patent and any future ANDA approvals for MSN. The outcome suggests Catalyst recognised litigation risk sufficient to negotiate rather than litigate to final judgment.
Generic entry risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Catalyst Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of US8772497B2 covering amifampridine synthesisSearch in Eureka ↗ |
| Defendant | MSN Laboratories Private Limited | Individual | Indian generic drug manufacturer and its U.S. affiliate pursuing ANDA entry for amifampridineSearch in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregory S. Gewirtz | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant counsel | Hoda Rifai-Bashjawish | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant counsel | KENDALL K. GURULE | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant counsel | Russell W. Faegenburg | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Daignault Iyer, LLP | Law Firm | Representing MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Lerner David, LLP | Law Firm | Representing MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Lerner, David, Littenberg, Krumholz & Mentlik, LLP | Law Firm | Representing MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s operative language — expressly prohibiting interference with MSN’s Paragraph IV certification under 21 U.S.C. — is analytically significant. Rather than simply ending the litigation, it functions as a contractual and judicial guarantee of MSN’s continued right to challenge the ‘497 patent through the ANDA pathway. This phrasing is consistent with settlements where the generic party resisted a full injunction or covenant not to sue, and instead negotiated a carve-out. The absence of any infringement or validity finding means neither party can cite this judgment as precedent on the merits of the ‘497 patent claims.
US8772497B2 — Method for Producing 1,2-Dihydropyridine-2-One Compounds
US8772497B2 (application no. US12/870507) protects a method for producing 1,2-dihydropyridine-2-one compounds — the chemical scaffold at the core of amifampridine phosphate, sold by Catalyst Pharmaceuticals as Firdapse. Process patents of this type are strategically distinct from composition-of-matter patents: they cover the how of manufacture rather than the molecule itself, meaning generic manufacturers must either design around the process or challenge the patent’s validity. The application date context suggests this patent was prosecuted to extend protection for the amifampridine franchise beyond any earlier compound patents.
For a specialty pharmaceutical company like Catalyst, a process patent listed in the Orange Book serves as a meaningful barrier to generic entry via the ANDA pathway even after compound exclusivity expires. Any generic filer referencing Catalyst’s Firdapse NDA must certify under Paragraph IV that the process patent is invalid or will not be infringed — triggering automatic 30-month stay litigation. The fact that MSN pursued and retained its Paragraph IV certification despite litigation signals this patent’s validity or enforceability is contestable, making it a key risk asset for both brand and generic competitors in the neuromuscular disorder drug space.
Should you run an FTO against US8772497B2?
Any company developing, manufacturing, or importing amifampridine or structurally related 1,2-dihydropyridine-2-one compounds for the U.S. market should treat US8772497B2 as a mandatory FTO checkpoint. Because this is a process patent, freedom-to-operate analysis must go beyond the molecule itself to examine every step in the proposed synthetic route. Even minor process differences may or may not clear the claims depending on claim scope — a question that requires independent legal analysis against the specific manufacturing process in question.
PatSnap Eureka’s FTO Search Agent accelerates this analysis by mapping US8772497B2 claim elements against published prior art, related process patents in the amifampridine and pyridine compound space, and the prosecution history. Eureka can flag related process claims from other assignees, identify design-around routes documented in the literature, and surface any continuation or divisional applications that may extend the claim family. R&D teams assessing generic entry timelines or API sourcing strategies should initiate FTO review before process finalisation.
Run a freedom-to-operate analysis on US8772497B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Patent Cases Involving Process Chemistry Patents
Explore comparable ANDA infringement actions litigated in the District of New Jersey involving Orange Book process patents and Paragraph IV certifications in specialty pharma.
What this case signals for the pharmaceutical patent IP landscape
Hatch-Waxman consent judgments with preserved Paragraph IV rights are strategically significant — and increasingly common in specialty pharma.
Paragraph IV preservation clauses are a key negotiating lever in ANDA disputes
When a consent judgment explicitly preserves the generic party’s Paragraph IV certification, it signals that validity and non-infringement were not resolved on the merits. Patent holders in similar positions should assess whether such clauses in settlement agreements expose them to further IPR petitions or ANDA-related declaratory judgment actions down the line.
Consent judgments in Hatch-Waxman cases rarely reflect the full commercial picture
The public record here discloses only the legal mechanism — not royalty rates, launch dates, or licensing terms. Industry practitioners should treat the filed consent order as the floor of disclosure, not the ceiling of agreement. Monitoring FDA Orange Book delisting or new patent listings alongside ANDA approval timelines provides a fuller competitive intelligence picture.
Catalyst v MSN — key questions answered
The consent judgment closed the case without resolving infringement or validity on the merits. Its key operative term is that MSN is expressly permitted to maintain its Paragraph IV certification against US8772497B2 under 21 U.S.C., preserving MSN’s legal right to continue pursuing ANDA approval for amifampridine.
Retaining the Paragraph IV certification means MSN’s ANDA challenge to US8772497B2 remains live. MSN has not conceded validity or infringement, and the patent remains subject to future challenge. This is consistent with settlements where generic companies negotiate entry terms while preserving challenge rights rather than accepting a permanent injunction.
US8772497B2 claims a method for producing 1,2-dihydropyridine-2-one compounds, the synthesis pathway for amifampridine — the active ingredient in Catalyst’s Firdapse. Listed in the FDA Orange Book, it triggers 30-month stay litigation when Paragraph IV-certified by ANDA filers, making it a key exclusivity asset for Catalyst in the treatment of Lambert-Eaton myasthenic syndrome.
The District of New Jersey is the principal venue for Hatch-Waxman ANDA litigation in the United States, given the concentration of pharmaceutical companies and regulatory expertise in the region. MSN Pharmaceuticals, Inc. — the U.S. affiliate — likely has a presence or registered agent there, providing personal jurisdiction alongside the court’s established pharmaceutical IP docket.
Catalyst was represented by Gibbons PC and Sterne Kessler Goldstein & Fox, with attorneys Charles H. Chevalier, Christine A. Gaddis, and Dennies Varughese. MSN was represented by Lerner David LLP (including Lerner, David, Littenberg, Krumholz & Mentlik) and Daignault Iyer LLP, with Gregory S. Gewirtz, Hoda Rifai-Bashjawish, Kendall K. Gurule, and Russell W. Faegenburg appearing for the defence.
PatSnap Eureka searches patents and litigation data to answer instantly.